Orthogonal Tri‐Modular Coiled‐Coil Assembly for Programmable Multi‐Cargo Display on Escherichia Coli Nissle 1917

Why It Matters

TriSCs transform live biotherapeutic products from static delivery vehicles into adaptable, multi‑functional platforms, expanding therapeutic precision and on‑demand reconfiguration.

Key Takeaways

• Orthogonal coiled‑coil motifs enable reversible cargo binding
• Three α‑helical modules displayed on E. coli Nissle surface
• Simultaneous DR5 and EGFR nanobodies boost anticancer efficacy
• Fluorescent reporter allows real‑time imaging of bacteria
• Mix‑and‑go assembly eliminates need for genetic fusions

Pulse Analysis

Live biotherapeutic products (LBPs) are gaining traction as living medicines that can act directly at disease sites. Traditional surface engineering of LBPs relies on permanent genetic fusions or covalent chemistries, which restrict the number of functional modules and prevent post‑manufacturing reconfiguration. The TriSC platform addresses these constraints by embedding three distinct α‑helical coiled‑coil motifs into the outer membrane of *E. coli* Nissle 1917, creating an orthogonal, self‑assembling interface that can recruit a variety of payloads on demand.

The core innovation lies in the orthogonal coiled‑coil system, which ensures that each motif binds only its designated partner peptide, allowing reversible and simultaneous attachment of multiple cargos. Researchers demonstrated rapid payload exchange by simply adding or removing nanobody‑peptide conjugates, and they incorporated a fluorescent reporter to monitor bacterial localization in real time. This modularity eliminates the need for extensive genetic redesign when swapping therapeutic agents, dramatically accelerating development cycles and enabling personalized treatment regimens.

Clinically, the ability to co‑display a DR5 agonistic nanobody with an EGFR‑targeting nanobody on a single bacterial chassis resulted in markedly enhanced tumor cell killing compared with soluble mixtures, highlighting the therapeutic advantage of spatially organized signaling. Beyond oncology, the platform’s imaging capability and reversible assembly open avenues for targeted drug delivery, microbiome modulation, and diagnostic biosensing. As the field moves toward precision theranostics, TriSCs provide a versatile foundation for programmable, multi‑cargo LBPs that can adapt to evolving clinical needs.